Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial

Anderson, James W., Greenway, Frank L., Fujioka, Ken, Gadde, Kishore M., McKenney, James, O'Neil, Patrick M.·2002·Obesity Research
DOI 10.1038/oby.2002.86

Cited by (314)

Items 101–200 of 314

  1. Drugs in the Pipeline for the Obesity Market
    David Charles Klonoff, Frank L. Greenway · 2008 · Journal of Diabetes Science and Technology
  2. Combination Drugs for Treating Obesity
    Frank L. Greenway, George A. Bray · 2010 · Current Diabetes Reports
  3. Historical and cultural aspects of obesity: From a symbol of wealth and prosperity to the epidemic of the 21st century
    Marta Sumińska, Rafał Podgórski, Klaudia Bogusz‐Górna, Bogda Skowrońska, Artur Mazur, Marta Fichna · 2022 · Obesity Reviews
  4. Method‐of‐use study of naltrexone sustained release ( SR )/bupropion SR on body weight in individuals with obesity
    Amy E. Halseth, Kevin Shan, Brandon Walsh, Kye M. Gilder, Ken Fujioka · 2016 · Obesity
  5. Pathophysiology of Obesity: Why Surgery Remains the Most Effective Treatment
    Talat Waseem, Kris M. Mogensen, David B. Lautz, Malcolm K. Robinson · 2007 · Obesity Surgery
  6. Combinations of drugs in the Treatment of Obesity
    Bruno Halpern, Eduardo S. L. Oliveira, André Murad Faria, Alfredo Halpern, Maria Edna de Melo, Cíntia Cercato, Márcio C. Mancini · 2010 · Pharmaceuticals
  7. Obesity
    Kerri Palamara, Harriette Rosen Mogul, Stephen J. Peterson, William H. Frishman · 2006 · Cardiology in Review
  8. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
    C. Tek · 2016 · Patient Preference and Adherence
  9. Treating the Chronic Disease of Obesity
    Gossmann, Mona, Butsch, W. Scott, Jastreboff, Ania M. · 2021 · Medical Clinics of North America
  10. Drugs for Treating Obesity
    Donna H. Ryan · 2021 · Handbook of experimental pharmacology
  11. Targeting central melanocortin receptors: a promising novel approach for treating alcohol abuse disorders
    Jeffrey J. Olney, Montserrat Navarro, Todd E. Thiele · 2014 · Frontiers in Neuroscience
  12. Drug Insight: appetite suppressants
    George A. Bray · 2005 · Nature Clinical Practice Gastroenterology &#38 Hepatology
  13. Cardiovascular Effects of the New Weight Loss Agents
    Matthew Vorsanger, Pritha Subramanyam, HOWARD S. WEINTRAUB, Steven H. Lamm, James A. Underberg, Eugenia Gianos, Ira J. Goldberg, Arthur Z. Schwartzbard · 2016 · Journal of the American College of Cardiology
  14. Tolerance does not develop to the decrease in nicotine self‐administration produced by repeated bupropion administration
    Anthony S. Rauhut, Linda P. Dwoskin, Michael Thomas Bardo · 2005 · Nicotine & Tobacco Research
  15. Pharmacological Treatment of Obesity
    Dhiraj G. Kabra, Uma Dhiraj Kabra, Matthias H. Tschöp, Susanna M. Hofmann · 2012 · Springer eBooks
  16. Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation in obese diabetic rats fed high-fat diet
    Mohammed Abdalla Hussein · 2011 · Free Radicals and Antioxidants
  17. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage
    James W. Anderson · 2007 · Expert Opinion on Pharmacotherapy
  18. Clinical Pharmacology of Sleep
    Seithikurippu Ratnas Pandi-Perumal, Jaime M. Monti · 2006 · Birkhäuser Basel eBooks
  19. Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash
    Fiona Wright, R. John Rodgers · 2013 · Psychopharmacology
  20. Stimulants for the Control of Hedonic Appetite
    Alison Sally Poulton, Emily Hibbert, Bernard Linton Champion, Ralph Kay Heinrich Nanan · 2016 · Frontiers in Pharmacology
  21. Impulsivity is associated with blood pressure and waist circumference among adolescents with bipolar disorder
    Melanie R. Naiberg, Dwight F. Newton, Jordan E. Collins, Christopher R. Bowie, Benjamin I. Goldstein · 2016 · Journal of Psychiatric Research
  22. Differential Treatment Benet Prediction for Treatment Selection in Depression: A Deep Learning Analysis of STAR*D and CO-MED Data
    Joseph Mehltretter, Robert Fratila, David A. Benrimoh, Adam D. Kapelner, Kelly Perlman, Emily Snook, Sonia Ancoli Israel, Caitrin Armstrong, Marc Miresco, Gustavo Turecki · 2020 · Computational Psychiatry
  23. Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?
    Carl Alexander Roberts, Paul Christiansen, Jason C. G. Halford · 2017 · Acta Diabetologica
  24. Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study
    Carmela Calandra, Rina Giuseppa Russo, Maria Luca · 2011 · Psychiatric Quarterly
  25. Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models
    Jason R. Clapper, Jennifer Athanacio, Carrie Wittmer, Peter S. Griffin, Lawrence J. D’Souza, David G. Parkes, Jonathan David Roth · 2012 · European Journal of Pharmacology
  26. Investigational therapies in the treatment of obesity
    Márcio C. Mancini, Alfredo Halpern · 2006 · Expert Opinion on Investigational Drugs
  27. Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia
    Lyu, Xuechan, Du, Jiang, Zhan, Guilai, Wu, Yujie, Su, Hang, Zhu, Youwei, Jarskog, Fredrik, Zhao, Min, Fan, Xiaoduo · 2018 · Frontiers in Pharmacology
  28. The body asks and the mind judges: Food cravings in eating disorders
    Oliveira, J., Cordás, T.A. · 2020 · L'Encéphale
  29. Drug Treatment of Obesity
    George A. Bray · 2005 · Psychiatric Clinics of North America
  30. Epidemiology of Obesity and Pharmacologic Treatment Options
    Shettar, Vignesh, Patel, Sarang, Kidambi, Srividya · 2017 · Nutrition in Clinical Practice
  31. Cardiovascular Risks and Benefits of Medications Used for Weight Loss
    Carolyn T. Bramante, Sarah J. Raatz, Eric Morris Bomberg, Megan O. Bensignor, Justin R. Ryder · 2020 · Frontiers in Endocrinology
  32. Medical Therapy for Obesity—Current Status and Future Hopes
    George A. Bray · 2007 · Medical Clinics of North America
  33. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice
    Kishore M. Gadde · 2014 · Expert Opinion on Pharmacotherapy
  34. Medications for Obesity: Mechanisms and Applications
    George A. Bray · 2009 · Clinics in Chest Medicine
  35. Emerging pharmacotherapy for obesity
    Louis J. Aronne, Amanda G. Powell, Caroline Margaret Apovian · 2011 · Expert Opinion on Emerging Drugs
  36. The effect of N-acetylcysteine or bupropion on methamphetamine self-administration and methamphetamine–triggered reinstatement of female rats
    Sergios Charntikov, Steven T. Pittenger, C. Pudiak, Rick A. Bevins · 2018 · Neuropharmacology
  37. Drug‐Induced Hyperphagia: What Can We Learn From Psychiatric Medications?
    Gordon Lee Jensen · 2008 · Journal of Parenteral and Enteral Nutrition
  38. Bupropion Treatment of Olanzapine-Associated Weight Gain: An Open-Label, Prospective Trial
    Gadde, Kishore M., Zhang, Wei, Foust, Mariko S. · 2006 · Journal of Clinical Psychopharmacology
  39. Obesity Management Interventions: A Review of the Evidence
    Joseph C. Yaskin, Richard W. Toner, Neil I. Goldfarb · 2009 · Population Health Management
  40. Medications for Weight Reduction
    George A. Bray · 2008 · Endocrinology and Metabolism Clinics of North America
  41. What are the risks and the benefits of current and emerging weight-loss medications?
    Jamie R. Robinson, Kevin Dean Niswender · 2009 · Current Diabetes Reports
  42. Pharmacological characterisation of the thermogenic effect of bupropion
    Yong-Ling Liu, Ian P. Connoley, David J. Heal, Michael J. Stock · 2004 · European Journal of Pharmacology
  43. Sustained-release Naltrexone/Bupropion A Novel Pharmacologic Approach to Obesity and Food Craving
    Ken Fujioka · 2014 · US Endocrinology
  44. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder
    Anastasiya Nestsiarovich, Berit Kerner, Aurélien Mazurie, Daniel C. Cannon, Nathaniel G. Hurwitz, Yiliang Zhu, Stuart J. Nelson, Tudor Ionel Oprea, Annette S. Crisanti, Mauricio F. Tohen et al. · 2019 · Psychoneuroendocrinology
  45. Pharmacotherapy in pediatric obesity: Current agents and future directions
    Abigail B. Wald, Naveen K. Uli · 2009 · Reviews in Endocrine and Metabolic Disorders
  46. Anti-obesity drugs
    Robert F. Kushner · 2008 · Expert Opinion on Pharmacotherapy
  47. Medical nutrition therapy for the treatment of obesity
    Raymond A Plodkowski, Sachiko T. St. Jeor · 2003 · Endocrinology and Metabolism Clinics of North America
  48. The Association of Antidepressant Medication and Body Weight Gain
    Sara Ranjbar, Nagesh Brahmavar Pai, Chao Deng · 2013 · CogPrints (University of Southampton)
  49. Weight-centric treatment of depression and chronic pain
    Wissam Ghusn, Celeste Bouchard, Mark A. Frye, Andres J Acosta · 2022 · Obesity Pillars
  50. Novel targets for the treatment of obesity: a review of progress
    Sharon C. Cheetham, Helen C. Jackson, Steve P. Vickers, Keith Dickinson, Robert B. Jones, David J. Heal · 2004 · Drug Discovery Today Therapeutic Strategies
  51. Diet and Female Sexual Health
    Maxwell M. Towe, Justin La, Farouk M. El‐Khatib, Natalie H. Roberts, Faysal A. Yafi, Rachel S. Rubin · 2019 · Sexual Medicine Reviews
  52. Obesity and Psychotropics
    Nikhil D. Nihalani, Thomas L. Schwartz, Umar A. Siddiqui, James L Megna · 2011 · CNS Neuroscience & Therapeutics
  53. Emerging drugs for obesity therapy
    Maria Teresa Zanella, Fernando Flexa Ribeiro Filho · 2009 · Arquivos Brasileiros de Endocrinologia & Metabologia
  54. Bupropion, Alone and in Combination with Naltrexone, Blunts Binge‐Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57 BL /6J Mice
    Montserrat Navarro, Kendall L. Luhn, Alexey B. Kampov‐Polevoy, James C. Garbutt, Todd E. Thiele · 2019 · Alcoholism Clinical and Experimental Research
  55. Advances in anti-obesity therapeutics
    Tung Ming Fong · 2005 · Expert Opinion on Investigational Drugs
  56. Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022
    Suzanne E. Cuda, Marisa Censani, Roohi Y. Kharofa, Valerie M. O’Hara, Rushika Conroy, Dominique R. Williams, Jennifer Paisley, Allen F. Browne, Sara Karjoo, Nancy Tkacz Browne · 2022 · Obesity Pillars
  57. Drugs to treat obesity: do they work?
    Sarah Kim · 2016 · Postgraduate Medical Journal
  58. Progressos recentes e novas perspectivas em farmacoterapia da obesidade
    André Murad Faria, Márcio C. Mancini, Maria Edna de Melo, Cíntia Cercato, Alfredo Halpern · 2010 · Arquivos Brasileiros de Endocrinologia & Metabologia
  59. Pharmacotherapy for obesity
    Lisa M. Neff, Louis J. Aronne · 2007 · Current Atherosclerosis Reports
  60. Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea
    Kyoung Kon Kim · 2019 · Korean Journal of Family Medicine
  61. Drug Treatment of Obesity
    George A. Bray, Donna H. Ryan · 2011 · Psychiatric Clinics of North America
  62. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity
    Khawla Fuad Ali, Alpana P. Shukla, Louis J. Aronne · 2015 · Expert Review of Clinical Pharmacology
  63. The Role of the Melanocortin System in Drug and Alcohol Abuse
    Montserrat Navarro · 2017 · International review of neurobiology
  64. An update on the pharmacological treatment of obesity
    David M. Schnee, Kathy Zaiken, William W. McCloskey · 2006 · Current Medical Research and Opinion
  65. Bupropion extended-release for depressive disorders
    James W. Jefferson · 2008 · Expert Review of Neurotherapeutics
  66. Drug Treatment of Obesity in Cardiovascular Disease
    Marietta Charakida, Nick Finer · 2012 · American Journal of Cardiovascular Drugs
  67. Pharmacologic Treatment Options for Obesity: Current and Potential Medications
    Ken Fujioka, Michael W. Lee · 2007 · Nutrition in Clinical Practice
  68. Obesity
    Helen M. Seagle, Holly R. Wyatt, James O. Hill · 2012 · Elsevier eBooks
  69. Tackling obesity: new therapeutic agents for assisted weight loss
    Samy McFarlane · 2010 · Diabetes Metabolic Syndrome and Obesity
  70. Does bupropion have advantages over other medical therapies in the cessation of smoking?
    Serena Tonstad, Joseph A. Johnston · 2004 · Expert Opinion on Pharmacotherapy
  71. Role of Bupropion Plus Naltrexone for the Management of Obesity
    Booth, Kemper, Clements, Jennifer N. · 2016 · Journal of Pharmacy Technology
  72. Update on pharmacology of obesity: benefits and risks.
    Lucio Cabrerizo García, Ana Maria Ramos-Levi, Carmen Moreno Lopera, Miguel Ángel Rubio · 2013 · PubMed
  73. The Effective Use of Anti-obesity Medications
    Sarah H. Schmitz, Louis J. Aronne · 2023 · Gastroenterology Clinics of North America
  74. Pharmacological treatment of obesity in children and adolescents: current status and perspectives
    Natalia Paola Catoira, Mara Nagel, Guillermo Di Girolamo, Claudio Daniel González · 2010 · Expert Opinion on Pharmacotherapy
  75. Medications for Weight Reduction
    George A. Bray · 2011 · Medical Clinics of North America
  76. Monoaminergic‐based Pharmacotherapy for Depression
    George I. Papakostas, Maurizio Fava M. D · 2005 · Wiley eBooks
  77. Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery
    Chika Vera Anekwe, Michael G. Knight, Sujatha Seetharaman, Wesley P. Dutton, Shradha M. Chhabria, Fatima Cody Stanford · 2021 · Current Treatment Options in Gastroenterology
  78. Obesity Primer for the Practicing Gastroenterologist
    Pichamol Jirapinyo, Christopher C. Thompson · 2021 · The American Journal of Gastroenterology
  79. Pharmacotherapy for obesity
    Kyoung Kon Kim · 2011 · Journal of Korean Medical Association
  80. Pharmacotherapy for the Obese Patient
    Lori M. Dickerson, Peter J. Carek · 2009 · Primary Care Clinics in Office Practice
  81. Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation
    Mo Yang, Hua Chen, Michael L. Johnson, Ekere James Essien, Ronald J. Peters, Xin Wang, Susan Abughosh · 2016 · Substance Use & Misuse
  82. Lo último en diagnóstico y tratamiento de la obesidad: ¿Hay lugar aún para la terapia conservadora?
    Ada M. Cuevas, María Soledad Reyes S · 2005 · Revista médica de Chile
  83. Managing comorbid obesity and depression through clinical pharmacotherapies
    Susan L. McElroy, Anna I. Guerdjikova, Nicole N. Mori, Paul E. Keck · 2016 · Expert Opinion on Pharmacotherapy
  84. ERNEST COST action overview on the (patho)physiology of GPCRs and orphan GPCRs in the nervous system
    Necla Birgül İyison, Clauda Abboud, Dayana Abboud, Abdulrasheed O. Abdulrahman, Ana‐Nicoleta Bondar, Julie Dam, Zafiroula Georgoussi, Jesús Giraldo, Anemari Horvat, Christos Karoussiotis et al. · 2024 · British Journal of Pharmacology
  85. HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats
    Karolina Pytka, Monika Głuch‐Lutwin, Joanna Knutelska, Magdalena Jakubczyk, Anna Maria Waszkielewicz, Magdalena Kotańska · 2016 · PLoS ONE
  86. Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats
    Gilvanildo Roberto da Silva, Mariane Gomes Carneiro, Miriam Pereira Barbosa, Jaciane de Almeida Costa, Ivone Antônia de Souza, Lisiane dos Santos Oliveira, Diogo Antônio Alves de Vasconcelos, Elizabeth do Nascimento, Rhowena Jane Barbosa de Matos, Sandra Lopes de Souza et al. · 2022 · Journal of Endocrinology
  87. Pharmacological Treatment of the Overweight Patient
    2007 · Humana Press eBooks
  88. Dietary and Medical Therapy of Obesity
    Phyllis Stumbo, Donna Hemingway, William Geoffrey Haynes · 2005 · Surgical Clinics of North America
  89. Pharmacologic management of obesity
    Robert F. Kushner · 2011 · Pediatric Blood & Cancer
  90. Efficacy of Naltrexone/Bupropion in Treatment of Binge Eating: A Systematic Review and Meta-Analysis
    Mostafa Hossam El Din Moawad, Mohammed Ahmed Sadeq, Abdallah Abbas, Reem Mohamed Farouk Ghorab, Ibrahim Serag, Mohamed Hendawy, Muhammad Abdullatif Alkasaby · 2024 · Psychiatry International
  91. Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity
    Nicholas T. Bello · 2019 · Expert Opinion on Drug Safety
  92. Prescription for Obesity: Eat Less and Move More. Is It Really That Simple?
    Karen M. Deck, Beth Haney, Camille F. Fitzpatrick, Susanne J. Phillips, Susan M. Tiso · 2014 · Open Journal of Nursing
  93. Attention Deficit/Hyperactivity Disorder and the Clinical Management of Obesity
    Sherry Pagoto, Carol Curtin, Bradley M. Appelhans, Miguel Alonso‐Alonso · 2012 · Current Obesity Reports
  94. Metabolic Influences of Commonly used Antidepressants on Blood Glucose Homeostasis
    H. Meng, Lu Ji, X. Zhang · 2019 · Indian Journal of Pharmaceutical Sciences
  95. Tratamiento médico de la obesidad mórbida: alternativas actuales, límites y perspectivas
    A. Miguel Rubio, Carmen Moreno · 2004 · Cirugía Española
  96. PhenotypicIn VivoScreening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates
    Michael S. Saporito, Christopher A. Lipinski, Andrew G. Reaume · 2012
  97. 3D printed mucoadhesive bupropion hydrochloride buccal thin films using Liquid Crystal Display
    Chrystalla Protopapa, Angeliki Siamidi, Laura Andrade Junqueira, Siva Satyanarayana Kolipaka, Hossam Ahmed, Joshua Siaw Boateng, Dennis Douroumis, Marilena Vlachou · 2025 · Journal of Drug Delivery Science and Technology
  98. Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study
    Jess G. Fiedorowicz, Lisa C. Brown, James Li, Sagar V. Parikh, Boadie Waid Dunlop, Brent P. Forester, Richard Charles Shelton, Michael E. Thase, Matthew Macaluso, Kunbo Yu et al. · 2025 · Psychopharmacology Bulletin
  99. Bupropion/naltrexone fixed-dose combination for the treatment of obesity
    Bruno Halpern, Faria, A.M., Alfredo Halpern · 2011 · Drugs of today
  100. Bupropion promotes alterations in the spermatogenesis of mice and congenital malformations in the offspring
    Eliane S. Sanches, Felipe Tsuzuki, Fábio A. Joinhas, Caio Cézar Nantes Martins, Glaura Scantamburlo Alves Fernandes, Maria José Sparça Salles · 2018 · Reproduction Fertility and Development